Based on the univariate analysis, sex, platelet count, AFP level, APRI, FIB‐4 index, the presence of cirrhosis, and number of curative treatments for HCC before the DAA therapy were identified as factors that were significantly associated with HCC recurrence after the DAA therapy. This evidence concerns the gene AFP and hepatocellular carcinoma.